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•  Post hoc analysis suggests compliance to chemotherapy & radiotherapy in 
radical chemoradiotherapy is clinically important 
•  Compliance should be considered as a prognostic factor in future studies 
•  Extending overall treatment time of radical chemoradiotherapy (50.4Gy) in 
anal cancer is associated with poorer outcomes 
•  Poor week 5 chemotherapy compliance is associated with an adverse impact 
on progression free and overall survival 
•  Careful patient selection as regards renal function and continual monitoring of 







Purpose: Concurrent chemoradiation is standard-of-care for patients with squamous 
cell carcinoma of the anus (SCCA). Poor compliance to chemotherapy, radiotherapy 
treatment interruptions and unplanned breaks may impact adversely on long-term 
outcomes.  
 
Methods: The ACT II trial recruited 940 patients with localized SCCA, and assigned 
patients to mitomycin (week 1) or cisplatin (weeks 1 and 5), with fluorouracil (weeks 
1 & 5) and radiotherapy (50·4Gy in 28 fractions over 38 days). This post-hoc 
analysis examined the association between baseline factors (age, gender, site, T-
stage and N-stage), and compliance to treatment (radiotherapy and chemotherapy), 
and their effects on loco-regional failure-free survival (LRFFS), progression-free 
survival (PFS) and overall survival (OS).  
 
Compliance was categorized into groups. Radiotherapy: 6 groups according to total 
dose (TD) and overall treatment time (OTT). Chemotherapy: 3 groups (A = per-
protocol; B = dose reduction or delay; C = omitted).  
 
Results: 931/940 patients were evaluable for radiotherapy and 936 for 
chemotherapy compliance. Baseline Glomerular filtration rate (GR) <60 mL/min and 
cisplatin were significantly associated with poor week 5 compliance to chemotherapy 
(p 0.003 and 0.02, respectively). Omission of week 5 chemotherapy was associated 
with significantly worse LRFFS (HR 2.53 [1.33 to 4.82] p=0.005). Dose 
reductions/delays or omission of week 5 chemotherapy were associated with 
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significantly worse FPFS (HR: 1.56 [95%CI: 1.18-2.06], p=0.002 and HR: 2.39 
[95%CI: 1.44-3.98}, p=0.001, respectively) and OS (HR: 1.92 [95%CI: 1.41-2.63], 
p<0.001 and (HR: 2.88 [95%CI: 1.63-5.08], p<0.001, respectively). Receiving the 
target radiotherapy dose in >42 days is associated with worse PFS and OS (HR:1.72 
(95%CI:1.17-2.54), p=0.006).  
 
Conclusion:  Poor compliance to chemotherapy and radiotherapy were associated 
with worse LRFFS, PFS and OS. Treatment interruptions should be minimized, and 
OTT and TD maintained.  
 
Key words:  Squamous cell carcinoma of the anus, chemotherapy, radiotherapy, 
chemoradiation, combined modality, compliance. 
 











Introduction   
Standard treatment for localized squamous cell carcinoma of the anus (SCCA) is 
chemoradiation using concurrent fluorouracil and mitomycin C1,2 This combination 
has been tested in randomized trials3,4,5,6,7 and results in good outcomes for cT1/T2 
cancers7, but less so for cT3/T4 cancers7,8. Loco-regional failure is the predominant 
pattern of relapse7,9, potentially influenced by innate chemo/radio-resistance, sub-
therapeutic radiotherapy total dose (TD) delivered and poor chemotherapy 
compliance. 
 
Early phase III trials in SCCA planned breaks in treatment of 6-8 weeks to manage 
acute treatment-related toxicities3,4, Evidence for the importance of overall treatment 
time (OTT) exists in squamous carcinomas of the head and neck (SCCHN)10,11. 
Evidence in SCCA is inconsistent, but strict adherence to protocol achieved 
significantly better overall survival (OS)12 and suboptimal compliance to the planned 
radiotherapy TD adversely impacted on local control and OS13. More recent trials, 
without planned radiotherapy interruptions, reported high levels of acute toxicity to 
both modalities6,7, leading to poor compliance in some patients. With the increasing 
use of intensity modulated radiotherapy (IMRT), toxicity is reduced allowing a 
potential reduction in average OTT14. 
 
Since chemotherapy and radiotherapy independently enhances the other, 
compliance for each is required for optimum results. In the second United Kingdom 
Anal Cancer Trial (ACT II) the intention was to deliver a standard central axis tumour 
dose (irrespective of stage) of 50.4Gy in 28 fractions in 38 days. Other contemporary 
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trials used an initial dose of 45Gy, but were permissive, according to stage and 
response, as regards TD and number of fractions6,15.   
 
Compliance refers to conformity to trial recommendations with respect to timing, 
dose, and frequency of the intended radiotherapy or chemotherapy treatment. We 
could find no standard definition for radiotherapy compliance (TD or OTT) within 
chemoradiation schedules in SCCA, although the UK contemporary national 
guidance in 2015 recommended a maximum of 4 days’ extension to the OTT16. In 
contrast, the RTOG 9811 trial allowed treatment breaks up to 10 days6. Thus, ACT II 
is uniquely placed to reliably assess the impact of compliance in terms of TD, OTT 
and chemotherapy on cancer outcomes. The permissive design of the other 
randomised trials precludes such an analysis. 
 
The present analysis aimed to quantify compliance to radiotherapy (TD and OTT) 
and week 5 chemotherapy. We aimed to identify independent factors to predict 
better or worse compliance, and to investigate the impact on oncological outcomes 
i.e. loco-regional failure-free survival (LRFFS), progression-free survival (PFS) and 
OS). This is a relevant research question, which cannot be answered by only looking 





Materials and Methods 
Trial design and participants 
ACT II was a randomized factorial phase III trial with 940 patients enrolled between 
2001-2008, which investigated whether replacing mitomycin with cisplatin in the 
chemoradiation schedule improves complete response rate, and the impact of 
maintenance chemotherapy (fluorouracil/cisplatin) after chemoradiation. Methods 
and results have previously been reported7.  
Protocol Guidance and modifications for toxicity  
Radiotherapy:  All patients were to receive radiotherapy (50.4Gy in 28 daily fractions 
over 38 days), in two-phases to the International Commission on Radiation Units and 
Measurements (ICRU) intersection point. A Monday start for radiotherapy was 
recommended, but not mandated.  As such, planned OTT for those commencing 
treatment Monday to Wednesday or Thursday to Friday would be 38 and 40 days 
respectively. Protocol interruptions to radiotherapy were only recommended for 
haematological and gastrointestinal NCI Common Toxicity Criteria (CTC) grade 3 
and 4. The protocol did not encourage, but allowed clinician’s discretion to interrupt 
radiotherapy for moist skin desquamation, gastrointestinal and haematological 
toxicity. There was no guidance in the protocol about how, or when, to compensate 
for such interruptions. 
Chemotherapy:  Patients received fluorouracil 1000 mg/m² per day on days 1–4 
(week 1) and 29–32 (week 5) by continuous intravenous infusion with radiotherapy, 
and either, 12 mg/m² of mitomycin as an intravenous bolus on day 1 only (maximum 
single dose 20 mg), or 60 mg/m² of cisplatin by intravenous infusion on days 1 and 
29 (maximum single dose of 120 mg).  
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Patients with a calculated GFR of 50-60 ml/min were eligible only if the subsequently 
tested GFR was ≥ 50ml/min. Cisplatin and MMC dose reductions were prescribed for 
patients with a GFR of 50–59 mL/.    
Fluorouracil doses were reduced for week 5 chemotherapy in severe toxicity 
following week 1. Specifically, 25% and 50% dose reductions were recommended for 
grade 3 and 4 haematological toxicity respectively. Omission of fluorouracil was 
mandated in the case of G4 diarrhoea. Week 5 cisplatin was omitted if the GFR fell 
below 50ml/min. 
Radiotherapy interruptions for toxicity delayed chemotherapy, so that the two 
modalities were given together.  
Treatment compliance definition 
Per-protocol radiotherapy compliance was defined prior to analysis as completion of 
protocol radiotherapy 50.4Gy in 28 fractions within an OTT of 38-42 days (including 
up to 4 days for logistical problems and public holidays) i.e. 10% extension.  Poor 
radiotherapy compliance was therefore defined as extending >42 days. Table 1  
shows how we categorized radiotherapy and week 5 chemotherapy compliance.  
Statistical analysis 
Categorical variables were summarized in terms of frequency and percentage, and 
continuous variables in terms of median and range.  
The association between baseline factors and radiotherapy TD delivered was 
examined using Kruskall Wallis test. The OTT by groups 1-6 was evaluated using 
cox regression. Logistic regression assessed any association between baseline 
characteristics and the risk of radiotherapy interruptions due to toxicity and odds 
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ratios (OR), 95% CI and p-values are reported. Fisher’s exact test examined whether 
any baseline characteristics were associated with chemotherapy compliance.  
Kaplan-Meier plots and cox regression assessed the effect of 
radiotherapy/chemotherapy compliance (groups 1-6 and A-C) on PFS and OS with 
subgroup analysis by T-stage. To account for potential immortality bias, the time to 
event outcomes were measured as time from 7 weeks post registration until the 
event of interest, or date of last follow-up for censored patients. Hazard ratios (HR), 




Of 940 patients, 931 were evaluable for radiotherapy and 936 for chemotherapy 
compliance respectively [Figure 1].  Median follow-up was 5.1 years (95%CI: 5.0-
5.3). Table 2, shows baseline characteristics were similar amongst all patients, and 
amongst groups 1-6 and groups A-C, except week 5 chemotherapy delays and 
reductions were more common in the cisplatin arm and amongst patients with 
GFR≥60 mL/min. 
 
Previously reported compliance details7 have been updated. [Table 3].  The median 
radiotherapy TD was 50·4 Gy (range 5.6Gy – 56.7Gy, IQR 50·4–50·4) in a median of 
28 fractions (range 3-32). Median OTT for radiotherapy was 38 days (range 3-81 
days, IQR 38–39). 98/931 (11%) patients had at least one day’s interruption in 
radiotherapy documented due to toxicity, but the precise cause was not specified in 
82/98 patients (84%). A further 40/931 (4%) had interruptions due to non-toxicity (19 
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administrative i.e. machine breakdown, transport) 11 patient choice (weather, illness) 
and in 10 the reason was not specified. Only 18 patients had treatment interruptions 
of >8 days.  For the 15 patients in Group 6, the extension to OTT ranged from1-29 
days with a median of 7 days. Radiotherapy was completed as per-protocol in 
379/467 (81%) in the mitomycin arm and 377/464 (81%) in the cisplatin arm, 
respectively. There was no evidence of an association between baseline factors, 
type of chemotherapy (mitomycin, cisplatin), age, gender, clinical T or N stage, GFR, 
WBC and radiotherapy compliance [Table A1 & A2] .  
 
Adjusting for interruptions due to toxicity, we observed a statistically significant effect 
of radiotherapy OTT on PFS and OS - if patients receive less than the planned target 
dose or if the planned target dose is extended >42 days [Figure 2 and Online Table 
A3, Figure A1, Figure A2].  Patients who received the planned radiotherapy dose 
within 38-42 days had better outcomes. If OTT was extended >42 days, there was a 
significant increase in the risk of PFS event and death (PFS, HR: 1.58 (95%CI: 1.12 




Week 1 chemotherapy was delivered without reductions/delays to 99% of patients in 
both mitomycin (433/465) and cisplatin arms (429/464).  Chemotherapy delays or 
per-protocol reductions were uncommon; 32/465 (7%) in the mitomycin and 33/464 




Data on week 5 chemotherapy was available for 936 patients. No chemotherapy was 
administered to 35/936 (3.7%), and 14% (68/471) in the mitomycin and 21% 
(96/465) in the cisplatin arm had delays or reductions. Completion of week 5 
chemotherapy per-protocol was higher in the mitomycin arm 388/471 (82%) 
compared to the cisplatin arm 349/465 (75%). Poor compliance reflected acute 
toxicity, mainly haematological toxicity, worsening renal function, mucositis, 
diarrhoea and severe asthenia.  
 
There was no association between baseline factors and week 5 chemotherapy 
compliance, except for baseline GFR in mL/min (p=0.003) (Table A2 ). Patients with 
baseline GFR of ≥60mL/min were more likely to receive week 5 per-protocol 
chemotherapy, 711/891 (80%) compared with <60mL/min, 26/45 (58%). The week 5 
chemotherapy 5FU intensity is comparable in both the mitomycin and cisplatin arms. 
 
Dose reductions/delays or omission of week 5 chemotherapy were associated with 
worse LRFFS (HR:1.35 [0.92 to 1.98] p=0.13 and HR 2.53 [1.33 to 4.82] p=0.005 
respectively). There was a statistically significant association between receiving per-
protocol week 5 chemotherapy and PFS (p=0.0006) and OS (p<0.0001) [Figure 3, 
Table A4] . Omission of chemotherapy during chemoradiation was associated with 
>2-fold increase in the risk of a PFS event (HR: 2.39 (95%CI: 1.44 to 3.98), p=0.001) 
compared with patients who completed week 5 per-protocol and an increased risk of 
death (HR 2.88 (95%CI: 1.63 to 5.08), p<0.001). Patients who received week 5 
chemotherapy with delays/reductions compared with per-protocol, also had a 
significant increased risk of a PFS event (HR: 1.56 (95%CI: 1.18 to 2.06), p=0.002) 




There is evidence of an interaction between chemotherapy week 5 compliance and 
T-stage for PFS (p=0.04) and OS (p=0.04) (Table A4 and Fig 3 ). The findings 
suggest patients with more advanced T-stage (T3-4) who failed to receive per-
protocol week 5 chemotherapy have a worse PFS (p<0001) and an increased risk of 
death (p<0001) compared with per-protocol treatment (Table A5 ).  
 
Compliance varied within the 52 participating sites, particularly in the 16 (31%) which 
recruited <10 patients (Figure A3).  The impact of facility volumes and academic 
centres on outcomes has been highlighted in SCCHN17. In ACT II, these 16 hospitals 
treated 79 patients, 30 of whom (38%) did not complete per-protocol treatment, 
compared with 36 sites entering ≥10 patients where only 145/852 (17%) did not 
complete per-protocol treatment. Amongst sites recruiting ≥10 patients, the 
correlation between the number of patients recruited in each site and the percentage 
of patients who received radiotherapy as per-protocol was weak and not statistically 
significant (Spearman correlation coefficient=-0.20, p value = 0.24). 
 
Discussion 
ACT II mandated a TD (irrespective of stage) of 50.4Gy in 28 fractions in 38 days. 
This retrospective post-hoc analysis quantifies compliance of patients treated with 
chemoradiation in the trial. We demonstrated that extending OTT of radiation by >42 
days, and the omission of week 5 chemotherapy or reduced doses/delays are 
associated with inferior PFS and OS. This represents important information for 




Since the protocol mandates chemotherapy and radiation are delivered 
concomitantly, 40% of patients who had a delay of radiotherapy OTT >42 days, also 
had the week 5 chemotherapy delayed and/or dose reduced, but only 4% had no 
chemotherapy at all. The association between better chemotherapy week 5 
compliance in the patients who had RT as per protocol compared with patients who 
had RT prolonged with OTT >42 days (40.4% vs 13.76% [p<0.001], respectively, 
implies that the inability to deliver the radiotherapy in a timely fashion is the main 
driver of the poor outcomes. 
 
A retrospective pooled analysis of the RTOG 87-04 and RTOG 98-11 trials (Ben 
Josef 2010) concluded that total treatment time, but not duration of radiation therapy, 
has a detrimental effect on local failure and colostomy rate in anal cancer. However, 
a third received NACT and 62% of patients in RTOG 9811 required a treatment 
break resulting in an overall median OTT of 49 days and 302/644 (47%) patients 
received a total dose of only 45Gy. For these reasons, the data cannot be compared 
with our data in ACT II, which gave no NACT, used a mandated dose of 50.4Gy, and 
treatment breaks for skin toxicity were not permitted. 
 
The strength of the study is that the data was collected prospectively within the ACT 
II trial with a large number of patients in study arms with equal distribution of age, 
gender, clinical stage of disease, ECOG performance status, and localization of 
primary tumour (canal /margin). TD, the fraction size of radiation and hence 
biological equivalent dose (BED) and the chemotherapy protocols were highly 
homogeneous. In particular, the consistency of the OTT [median 38 days (IQR 38-39 
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days)] in both mitomycin and cisplatin groups strengthens our conclusions. 
Outcomes are also mature with a 5-year median follow-up.  
 
Quality assurance (QA) in radiotherapy has previously focussed on target 
delineation, dosimetry, PTV coverage or dose‐volume parameters, OTT has been 
less rigorously assessed. Compliance has been categorized as acceptable, 
unacceptable and other (no radiotherapy or incomplete radiotherapy due to death, 
progression or refusal)18. Some trials consider a tolerance of +/- 10% as per-protocol 
with >10% an unacceptable deviation19. In ACT II, the QA protocol did not specify 
how many days extension to OTT would classify minor or major deviations.  
 
The limitations of this study include the fact that this was an unplanned ‘post hoc’ 
retrospective analysis. The groups were retrospectively defined (based on 
contemporary UK recommendations and +/- 10% deviations), but the definitions 
were set prior to any analysis of data. Since patients are not randomized into these 
groups, sources of bias cannot be controlled for. Few patients failed to achieve per-
protocol compliance and hence these represent small subgroup analyses. 
 
Larger field sizes could have contributed to toxicity and compliance, but without 
reviewing individual field sizes in the light of staging CT and MRI scans to assess 
their fidelity, we are unable to provide detailed data. However, it is reassuring that 
median radiotherapy TD delivered, OTT for radiotherapy and risk of radiotherapy 
interruptions due to toxicity are similar between T1, T2, T3 and T4 tumours, and 
there is no evidence of a statistical difference (p= 0.68, p=0.47 and p=0.88 
respectively). Table A1.  Reductions/delays in week 5 chemotherapy was observed 
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in 15% for T1/T2 and 19% for T3/T4, with no statistically significant difference 
(p=0.37) Table A2. 
 
A further limitation is that we were unable to test for imbalances between the groups 
in human papilloma virus–associated cancer (p16+), smoking history or tumour 
infiltrating lymphocytes as this data was not collected and we were unable to adjust 
for co-morbidity. 
 
The association between compliance groups and outcomes can reflect an outcome-
by-outcome analysis, which is prone to bias as patients who complete per-protocol 
treatment tend to be younger, fitter, more robust, without co-morbidity and hence 
have a better prognosis. Any association between compliance and outcome does not 
therefore necessarily mean that the actual treatment received is associated with 
better/worse outcomes, although if other reasons such as poor adherence without 
toxicity and administrative issues can be shown to be responsible, then more robust 
associations can be drawn.  Our results show no difference in the proportion of 
patients with an OTT >42 days for patients > 65 years compared to younger patients. 
 
There are a number of potential strategies to improve compliance. Prospective data 
from the RTOG 0529 trial suggest IMRT reduces acute toxicity. Significant reductions 
were reported in grade 2+ hematologic (73% vs. 85%; P= .032), grade 3+ 
gastrointestinal (21% vs. 36%; P = 0.008), and grade 3+ dermatologic events (23% 
vs. 49%; P<0.0001)14.  Subsequent analyses suggested acute AEs correlated with 
radiation dose to the small bowel and anterior pelvic contents20 in keeping with the 
finding of improved toxicity using IMRT. This is similar to a UK audit of SCCA, where 
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reduced toxicity resulted in radiotherapy interruptions falling from 8%-4% with IMRT 
and patients completing planned radiotherapy TD rose from 90% to 96%21.  
 
Despite the use of IMRT, compliance remains an issue since treatment breaks in the 
51 assessable patients in the RTOG 0529 trial were required by 49%, compared with 
62% in RTOG 9811 (P=0.09), Median OTT with IMRT was 43 days with TD 54Gy, 
compared with 49 days and TD 50.4Gy in the standard fluorouracil/mitomycin arm of 
RTOG 9811l (P<0.0001)14.  Additionally, 8/51 (16%) patients did not complete per-
protocol chemotherapy. A recent retrospective pooled analysis of patients treated 
with IMRT in the UK reported failure to complete treatment or interruptions (defined 
as any extension >2 days over the planned OTT) as 5.2%. In multivariate analysis, a 
HR of 5.80 (1.96-17.29) was found in this group for persistent disease (p=0.001) 
compared with treatment delivered per-protocol22. Therefore, despite IMRT, poor 
compliance remains an issue.   
 
A retrospective analysis, using the National Cancer Data Base (NCDB), compared 
outcomes of patients with SCCA treated with IMRT or 3D-CRT23. They reported 
improved OS for those treated with shorter treatment times (P < .0001) and at high-
volume centers [>18 cases per-year] (P = .0011). A more recent NCDB analysis of 
CRT (2004–2014), also showed prolonging RT was independently associated with 
reduced OS - with most effect when RT was delayed >2 days24.  
 
Additional proactive strategies could further improve compliance. First, meticulous 
hydration in the first cycle of chemotherapy might minimize toxicity in patients with 
baseline GFR<60. Second, the association between absolute nadir and the V10/V20 
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of pelvic and lumbosacral bone marrow could be addressed by bone marrow 
sparing, optimising constraints and plan evaluation24. 
 
Data on chemotherapy compliance in SCCA is sparse (Table A6).  In the ACCORD 
03 trial 78/82 (95%) (Arm C) and 71/75 (95%) (Arm D) received the second cycle of 
concurrent chemotherapy in the 157 patients, who received chemoradiation without 
induction chemotherapy15. However, this second cycle was adjusted (50-75%) 
according to early toxicity.  
 
In ACT II, prolonged OTT in radiotherapy and poor compliance to week 5 
chemotherapy were associated with worse PFS and OS outcomes. The large 
randomised trial dataset with standardised radiotherapy fields and the same 
mandated total dose, protocol-defined chemotherapy and toxicity prospectively 
captured, increases the likelihood that our findings are applicable to routine clinical 
practice, and should have a significant impact on the delivery of treatment regimens. 
 
Although a ‘post hoc’ analysis is not powered for comparisons, the data can assist 
the design of future trials. We believe that there is an unmet need for studies to 
identify factors associated with compliance, and whether compliance could be used 
as a `marker’ predictive of the outcome. In this study, prolongation of OTT was not 
associated with any clinical factors, but initial GFR impacted on the ability to deliver 
week 5 chemotherapy in full.  
 
This analysis strongly suggests radiotherapy should be delivered per-protocol in a 
timely manner in high volume facilities, avoiding interruptions, to achieve optimal 
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treatment outcomes. Better outcomes are observed when week 5 chemotherapy is 
administered in full without dose reduction or delay. Patients with poor compliance 
may require closer monitoring following chemoradiation to identify local recurrence at 
an early stage.  
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Main Figures  
 
Figure 1:  Diagram of the evaluable patients for th e radiotherapy compliance 




Figure 2 Association between compliance with Overal l radiotherapy treatment 
time (OTT) and Loco-regional failure free survival (A), progression-free 
survival (B) and overall survival (C) 
 
Kaplan-Meier estimates of (A) loco-regional failure free survival (LRFFS), (B) 
progression-free survival (PFS), and (C) overall survival (OS) in the assessable 
population for mandated dose of 50.4Gy in 28 fractions over 38-42 days versus 50.4 
Gy with OTT >42 days. HR, hazard ratio CI confidence interval. 
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Figure 3. Association between compliance with week 5 chemotherapy and 
loco-regional failure free survival (A),  progression-free survival (B) and overall 
survival (C) 
 
Kaplan-Meier estimates of (A) loco-regional failure free survival (LRFFS), (B) 
progression-free survival (PFS), and (C) overall survival (OS) in the assessable 
population for week 5 chemotherapy delivered per protocol, for week 5 with 
reductions delays or both, and for week 5 chemotherapy omitted HR, hazard ratio CI 
confidence interval. 
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Radiotherapy comp liance  
1 
included patients who received radiotherapy treatment according to 
protocol (ie 50.4Gy in 38-42 days, normally done over 28 fractions of 
1.8Gy), which acted as the reference group.  
2 
included patients who received radiotherapy treatment but to a lower 
total dose of ≤40Gy.  
3 
included patients who received radiotherapy treatment to an 
intermediate dose between >40Gy to <48.60Gy in 20-28 fractions 
4 
included patients who received the full radiotherapy treatment of 
50.4Gy but within less than 38 days 
5 
included patients who received the full radiotherapy treatment of 
50.16 to 51.5 Gy but delivered in longer than 42 days (ie a treatment 
interruption or gap with no compensation for potential accelerated 
repopulation)  
6 
had an extended overall treatment time and had an increase in total 
dose >52.2Gy-56.7Gy in 29-32 fractions 
Week 5 chemotherapy compliance  
A Patients received week 5 chemotherapy as per protocol 
B 
Patients received week 5 chemotherapy with a dose reduction or 
delay 
C Patients where week 5 chemotherapy was omitted 








  Radiotherapy compliance 
N=931   





>40Gy to  
<48.60Gy 
(G3) 
Received 50.40Gy >52.20Gy 
(G6) 






 <38 days (G4) 
38-42 days  
(G1) 
>42 days  
(G5)  
N (%) 




















<65 years 699 (74%) 4 (50%) 19 (76%) 22 (67%) 565 (75%) 70 (74%) 13 (87%) 554 (75%) 115 (70%) 26 (74%) 
≥65 years 241 (26%) 4 (50%) 6 (24%) 11 (33%) 191 (25%) 24 (26%) 2 (13%) 183 (25%) 49 (30%) 9 (26%) 
Sex 
Female 587 (62%) 5 (63%) 16 (64%) 21 (64%) 477 (63%) 56 (60%) 10 (67%) 449 (61%) 112 (68%) 24 (69%) 
Male 353 (38%) 3 (38%) 9 (36%) 12 (36%) 279 (37%) 38 (40%) 5 (33%) 288 (39%) 52 (32%) 11 (31%) 
Site of primary tumour 
Canal 787 (84%) 7 (88%) 20 (80%) 28 (85%) 631 (83%) 81 (86%) 12 (80%) 607 (82%) 145 (88%) 32 (91%) 
Margin 132 (14%) 1 (13%) 5 (20%) 4 (12%) 110 (15%) 10 (11%) 2 (13%) 113 (15%) 16 (10%) 3 (9%) 
Not reported 21 (2%) 0 (0%) 0 (0%) 1 (3%) 15 (2%) 3 (3%) 1 (7%) 17 (2%) 3 (2%) 0 (0%) 
T stage 
T1 91 (10%) 2 (25%) 5 (20%) 5 (15%) 73 (10%) 4 (4%) 2 (13%) 71 (10%) 17 (10%) 3 (9%) 
T2 395 (42%) 4 (50%) 9 (36%) 6 (18%) 325 (43%) 43 (46%) 7 (47%) 322 (44%) 57 (35%) 14 (40%) 
T3 295 (31%) 2 (25%) 5 (20%) 18 (55%) 234 (31%) 26 (28%) 5 (33%) 220 (30%) 59 (36%) 15 (43%) 
T4 135 (14%) 0 (0%) 5 (20%) 4 (12%) 106 (14%) 18 (19%) 0 (0%) 108 (15%) 24 (15%) 3 (9%) 
Tx/Not reported 24 (3%) 0 (0%) 1 (4%) 0 (0%) 18 (2%) 3 (3%) 1 (7%) 16 (2%) 7 (4%) 0 (0%) 
Nodal stage 
Negative 587 (62%) 7 (88%) 17 (68%) 14 (42%) 481 (64%) 58 (62%) 5 (33%) 464 (63%) 98 (60%) 23 (66%) 
Positive 305 (32%) 1 (13%) 8 (32%) 14 (42%) 238 (31%) 33 (35%) 8 (53%) 237 (32%) 60 (37%) 7 (20%) 
Nx/Not reported 48 (5%) 0 (0%) 0 (0%) 5 (15%) 37 (5%) 3 (3%) 2 (13%) 36 (5%) 6 (4%) 5 (14%) 
GF rate in mL/min 
<60 45 (5%) 1 (13%) 3 (12%) 2 (6%) 34 (4%) 3 (3%) 1 (7%) 26 (4%) 16 (10%) 3 (9%) 
≥60 895 (95%) 7 (88%) 22 (88%) 31 (94%) 722 (96%) 91 (97%) 14 (93%) 711 (96%) 148 (90%) 32 (91%) 
Differentiation 
Well 121 (13%) 1 (13%) 3 (12%) 3 (9%) 102 (13%) 10 (11%) 2 (13%) 102 (14%) 14 (9%) 5 (14%) 
Moderate 395 (42%) 5 (63%) 10 (40%) 14 (42%) 307 (41%) 51 (54%) 5 (33%) 311 (42%) 75 (46%) 8 (23%) 
Poor 277 (29%) 1 (13%) 6 (24%) 7 (21%) 229 (30%) 26 (28%) 4 (27%) 214 (29%) 49 (30%) 14 (40%) 
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Unknown/Not reported 147 (16%) 1 (13%) 6 (24%) 9 (27%) 118 (16%) 7 (7%) 4 (27%) 110 (15%) 26 (16%) 8 (23%) 
Tumour type 
Basaloid 108 (11%) 0 (0%) 3 (12%) 7 (21%) 88 (12%) 9 (10%) 1 (7%) 85 (12%) 20 (12%) 3 (9%) 
Cloacogenic 14 (1%) 0 (0%) 1 (4%) 0 (0%) 12 (2%) 1 (1%) 0 (0%) 11 (1%) 3 (2%) 0 (0%) 
Squamous 769 (82%) 8 (100%) 19 (76%) 25 (76%) 615 (81%) 81 (86%) 13 (87%) 601 (82%) 135 (82%) 30 (86%) 
Not reported 49 (5%) 0 (0%) 2 (8%) 1 (3%) 41 (5%) 3 (3%) 1 (7%) 40 (5%) 6 (4%) 2 (6%) 
Pretreatment colostomy 
No 806 (86%) 7 (88%) 21 (84%) 28 (85%) 649 (86%) 80 (85%) 13 (87%) 641 (87%) 133 (81%) 30 (86%) 
Yes 131 (14%) 1 (13%) 4 (16%) 5 (15%) 104 (14%) 14 (15%) 2 (13%) 94 (13%) 31 (19%) 5 (14%) 
Not reported 3 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (0%) 0 (0%) 0 (0%) 2 (0%) 0 (0%) 0 (0%) 
WBC in x 109/l 
<11 739 (79%) 5 (63%) 21 (84%) 28 (85%) 599 (79%) 67 (71%) 14 (93%) 575 (78%) 138 (84%) 25 (71%) 
≥11 189 (20%) 2 (25%) 4 (16%) 5 (15%) 151 (20%) 26 (28%) 1 (7%) 159 (22%) 25 (15%) 4 (11%) 
Not reported 12 (1%) 1 (13%) 0 (0%) 0 (0%) 6 (1%) 1 (1%) 0 (0%) 3 (0%) 1 (1%) 6 (17%) 
Treatment 
Mitomycin 472 (50%) 3 (38%) 11 (44%) 16 (48%) 379 (50%) 51 (54%) 7 (47%) 388 (53%) 68 (41%) 15 (43%) 
Cisplatin 468 (50%) 5 (63%) 14 (56%) 17 (52%) 377 (50%) 43 (46%) 8 (53%) 349 (47%) 96 (59%) 20 (57%) 




Table 3: Descriptive statistics for radiotherapy an d week 5 chemotherapy 
compliance 
Radiotherapy 
Radiotherapy  Total 
N=931 
  
 (Median, range) 
Total dose delivered Gy  50.4 (5.4 – 56.7) 
Time on radiotherapy  38 (3-81) 
Number of fractions  28 (3-32) 
Radiotherapy Interruptions 
Due to toxicity 














Completed week 5 as per protocol 388 (82%) 349 (75%) 737 (78%) 
Any delays, dose reduction or both 68 (14%) 96 (21%) 164 (17%) 
No chemo during chemoradiation 15 (3%) 20 (4%) 35 (4%) 
Insufficient data 1 (<1%) 3 (1%) 4 (0%) 
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Table A1: Association between baseline factors and radiotherapy compliance 
Explanatory factors 
Outcome of interest  
Radiotherapy total dose delivered 
N=931 
  
Patients who received the target dose 50.40 Gy 
Radiotherapy duration  
in days 
N=883   
Radiotherapy interruptions  
due to toxicity 
N=883 
N Median  
(range) 
p*  N 
Median  
(range) 
p** Events/N (%) OR (95%CI) p*** 
Age 
<65 years 693 50.4 (16.2 to 56.7) 
0.91 
657 38 (29 to 81) 
0.82 
61/657 (9%) 1.00 
0.56 
≥65 years 238 50.4 (5.4 to 55.8) 226 38 (32 to 59) 24/226 (11%) 1.16 (0.71 to 1.91) 
Gender  
Female 585 50.4 (5.4 to 56.7) 
0.79 
554 38 (29 to 81) 
0.88 
51/554 (9%) 1.00 
0.58 
Male 346 50.4 (9 to 54) 329 38 (33 to 56) 34/329 (10%) 1.14 (0.72 to 1.8) 
Site of primary tumour  
Canal 779 50.4 (5.4 to 56.7) 
>0.99 
740 38 (29 to 81) 
0.38 
72/740 (10%) 1.00 
0.99 
Margin 132 50.4 (30.6 to 52.2) 124 38 (33 to 50) 12/124 (10%) 0.99 (0.52 to 1.89) 
T stage  
T1 91 50.4 (5.4 to 55.8) 
0.68 
82 38 (29 to 49) 
0.47 
8/82 (10%) 1.00 
T2 394 50.4 (9 to 52.2) 374 38 (32 to 56) 38/374 (10%) 1.05 (0.47 to 2.33) 
0.88 T3 290 50.4 (30.6 to 56.7) 278 38 (32 to 59) 26/278 (9%) 0.95 (0.41 to 2.2) 
T4 133 50.4 (43.2 to 51.39) 128 38 (33 to 81) 10/128 (8%) 0.78 (0.3 to 2.08) 
Nodal stage  
Negative 582 50.4 (5.4 to 54) 
0.53 
553 38 (32 to 57) 
0.8 
53/553 (10%) 1.00 
0.96 
Positive 302 50.4 (30.6 to 56.7) 285 38 (32 to 81) 27/285 (9%) 0.99 (0.61 to 1.61) 
GF rate  in mL/min  
<60 44 50.4 (34.2 to 55.8) 
0.77 
39 38 (32 to 46) 
0.47 
3/39 (8%) 1.00 
0.68 
≥60 887 50.4 (5.4 to 56.7) 844 38 (29 to 81) 82/844 (10%) 1.29 (0.39 to 4.29) 
Differentiation  
Well 121 50.4 (16.2 to 52.2) 
0.87 
115 38 (34 to 56) 
0.62 
12/115 (10%) 1.00 
Moderate 392 50.4 (9 to 56.7) 372 38 (32 to 57) 36/372 (10%) 0.92 (0.46 to 1.83) 
0.97 
Poor 273 50.4 (5.4 to 55.8) 262 38 (33 to 81) 26/262 (10%) 0.95 (0.46 to 1.95) 
Tumour type  
Basaloid 108 50.4 (43.2 to 52.2) 
0.95 
104 38 (32 to 51) 
0.43 
11/104 (11%) 1.00 
Cloacogenic 14 50.4 (46.8 to 50.4) 13 38 (38 to 43) 2/13 (15%) 1.54 (0.3 to 7.85) 
0.81 
Squamous 761 50.4 (5.4 to 56.7) 721 38 (29 to 81) 71/721 (10%) 0.92 (0.47 to 1.81) 
Pretreatment colostomy  
No 798 50.4 (5.4 to 56.7) 
0.85 
757 38 (29 to 57) 
0.51 
76/757 (10%) 1.00 
0.22 
Yes 130 50.4 (21.6 to 54) 123 38 (33 to 81) 8/123 (7%) 0.62 (0.29 to 1.33) 
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WBC in x 109/l  
<11 734 50.4 (9 to 56.7) 
0.88 
694 38 (29 to 59) 
0.25 
69/694 (10%) 1.00 
0.49 
≥11 189 50.4 (5.4 to 52.2) 182 38 (37 to 81) 15/182 (8%) 0.81 (0.45 to 1.46) 
Treatment  
Mitomycin 467 50.4 (21.6 to 55.8) 
0.93 
446 38 (29 to 81) 
0.67 
43/446 (10%) 1.00 
0.99 
Cisplatin 464 50.4 (5.4 to 56.7) 437 38 (32 to 57) 42/437 (10%) 1 (0.64 to 1.56) 
* derived from Kruskall Wallis test 
** derived from cox regression 










Week 5 chemotherapy compliance  
N=936 Fishers'  












Age, N (%) 
<65 years 554 (80%) 115 (17%) 26 (4%) 
0.39 
≥65 years 183 (76%) 49 (20%) 9 (4%) 
Sex, N(%) 
Female 449 (77%) 112 (19%) 24 (4%) 
0.16 
Male 288 (82%) 52 (15%) 11 (3%) 
Site of primary tumour, 
N (%)     
Canal 607 (77%) 145 (18%) 32 (4%) 
0.11 
Margin 113 (86%) 16 (12%) 3 (2%) 
T stage, N  (%) 
T1 71 (78%) 17 (19%) 3 (3%) 
0.37 
T2 322 (82%) 57 (15%) 14 (4%) 
T3 220 (75%) 59 (20%) 15 (5%) 
T4 108 (80%) 24 (18%) 3 (2%) 
Nodal stage, N  (%) 
Negative 464 (79%) 98 (17%) 23 (4%) 
0.29 
Positive 237 (78%) 60 (20%) 7 (2%) 
GF rate in mL/min, N  (%) 
<60 26 (58%) 16 (36%) 3 (7%) 
0.003 
≥60 711 (80%) 148 (17%) 32 (4%) 
Differentiation, N  (%) 
Well 102 (84%) 14 (12%) 5 (4%) 
0.076 Moderate 311 (79%) 75 (19%) 8 (2%) 
Poor 214 (77%) 49 (18%) 14 (5%) 
Tumour type, N  (%) 
Basaloid 85 (79%) 20 (19%) 3 (3%) 
0.96 Cloacogenic 11 (79%) 3 (21%) 0 (0%) 
Squamous 601 (78%) 135 (18%) 30 (4%) 
Pretreatment colostomy, 
N (%)     
No 641 (80%) 133 (17%) 30 (4%) 
0.12 
Yes 94 (72%) 31 (24%) 5 (4%) 
WBC in x 109/l, N  (%) 
<11 575 (78%) 138 (19%) 25 (3%) 
0.14 
≥11 159 (85%) 25 (13%) 4 (2%) 
Treatment, N  (%) 
Mitomycin 388 (82%) 68 (14%) 15 (3%) 
0.02 
Cisplatin 349 (75%) 96 (21%) 20 (4%) 





Table A3: Association between radiotherapy complian ce and overall survival/progression-free survival 
Factors of interest 
Outcome of interest 
Overall Survival (OS)*   Progression-free survival (PFS)** 
Total events 








p   
Total events 









Radiotherapy compliance groups 
1)50.40Gy, 38-42 days 146/756 86% 1.00 (reference) 212/756 76% 1.00 (reference) 
2) ≤40Gy 5/7 29% 8.24 (3.35 to 20.27) p<0.001 5/7 29% 5.43 (2.24 to 13.21) p<0.001 
3) >40Gy to <48.60Gy 12/25 70% 3.12 (1.73 to 5.63) p<0.001  13/25 63% 2.12 (1.21 to 3.72) 0.009 
4) 50.40Gy, <38 days 6/33 87% 0.95 (0.42 to 2.16) 0.91  9/33 72% 1.00 (0.51 to 1.95) >0.99 
5) 50.40Gy, >42 days 31/94 78% 1.72 (1.17 to 2.54) 0.006 38/93 62% 1.57 (1.11 to 2.21) 0.01 
6) >52.20Gy 4/15 73% 1.57 (0.58 to 4.25) 0.37 6/15 59% 1.60 (0.71 to 3.59) 0.26 
          
Total dose delivered in Gy  
(continuous variable) in groups 1 
to 6 
204/930 84% 0.95 (0.93 to 0.98) p<0.001 
 
283/929 73% 0.96 (0.94 to 0.99) 0.006 
Duration of radiotherapy in 
weeks amongst groups 1), 4) 
and 5) 
         
Unadjusted 
183/883 85% 
1.34 (1.06 to 1.68) 0.01 
259/882 74% 
1.27 (1.02 to 1.59) 0.03 
Adjusted for interruptions due 
to toxicity 
1.36 (1.07 to 1.74) 0.01 
 
1.20 (0.92 to 1.57) 0.19 
                    
* Measured from 7 weeks post registration until death or time of last follow-up recorded. Patients who had the event of interest before 7 weeks or a follow-up 
of less than 7 weeks were excluded 
** Measured from 7 weeks post registration until occurrence of PFS event or time of last follow-up recorded. Patients who had the event of interest before 7 
weeks or a follow-up of less than 7 weeks were excluded  
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Table A4: Association between compliance with week 5 chemotherapy and overall survival/progression-fre e survival 
Compliance with week 5 chemotherapy 
Total events/ 
No of patients 
3 years  
rate % 
HR (95%CI) p 
Overall Survival (OS)*          
Completed week 5 as per protocol 139/737 86% 1.00 (reference) 
Any delays, dose reduction or both 55/164 77% 1.92 (1.41 to 2.63) p<0.001 
No chemo during chemoradiation 13/32 56% 2.88 (1.63 to 5.08) p<0.001 
Progression -free survival (PFS)**          
Completed week 5 as per protocol 206/736 75% 1.00 (reference) 
Any delays, dose reduction or both 65/164 66% 1.55 (1.17 to 2.04) 0.002 
No chemo during chemoradiation 16/32 51% 2.37 (1.43 to 3.95) 0.001 
          
* Measured from 7 weeks post registration until death or time of last follow-up recorded. Patients who had the event of interest 
before 7 weeks or a follow-up of less than 7 weeks were excluded 
** Measured from 7 weeks post registration until occurrence of PFS event or time of last follow-up recorded. Patients who had the 












A: Overall Survival by week 5 chemotherapy complian ce in T stage 1 & 2 and T-stage 3 & 4 
Overall Survival Interaction  p* 















HR (95%CI) p 
Completed week 5 as per protocol 
0.035 
62/394 89% 1 (base) 77/328 82% 1 (base) 
Any delays, dose reduction or both 14/74 94% 1.17 (0.66 to 2.10) 0.59 40/83 60% 2.43 (1.66 to 3.56) p<0.0001 
No chemo during CRT 7/16 54% 3.84 (1.75 to 8.41) 0.001 6/16 58% 2.11 (0.92 to 4.85) 0.078 
                    
 
 
B: Progression-free Survival by week 5 chemotherapy  compliance in T stage 1 & 2 and T-stage 3 & 4  
Progression-free Survival Interaction  p* 















HR (95%CI) p 
Completed week 5 as per protocol 
0.042 
62/393 81% 1 (base) 76/327 68% 1 (base) 
Any delays, dose reduction or both 14/74 86% 1.03 (0.62 to 1.71) 0.91 40/83 47% 2.04 (1.44 to 2.87) p<0001 
No chemo during Chemoradiation 7/16 49% 3.01 (1.46 to 6.22) 0.003 6/16 53% 1.99 (0.97 to 4.09) 0.06 
                    
* Interaction between T-stage* Chemo compliance 
 
 
Adjusting for the patient characteristics in table 2, the interaction between T-stage and chemotherapy compliance for PFS is p=0.05 and for OS p=0.05. 
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Table A6: title Summary of 3D chemoradiation trials  in SSCC 
Trial  Arms (number of patients) Chemo compliance CHEMORADIATION (CRT) compliance  
   Median RT total 
dose (Range) 
Median OTT in  
Days (Range) 
 
RTOG 9811 (Ajani 2008) 5FU/MMC Arm (341) 95% 55Gy (9-69 Gy) 
IQR 45.9-59 




 NACT + 5FU/cisplatin Arm (341) Induction NACT 94% 55Gy (14.4- 70.2) 
IQR 45-59 
45 (not given) 
IQR 37.5-52 
 
      
Accord 03 (Peiffert 2012) Arm A (75)  45Gy  (39.6-47.3) 35 (26-81)  
 Arm B (75) Induction NACT  45Gy  (39.4-47.3) 36 (25-91)  
 Arm C (82) standard 78/82 (95%) 45Gy   (42.4-50.0) 35 (30-65)  
 Arm D (75) 71/75 (95%) 45Gy   (34.2-47.3) 35 (25-74)  





















NACT = neoadjuvant chemoradiation 
MMC = mitomycin 
5FU = 5fluorouracil 
19 
 
Table A7 Patients who had RT as per protocol and co mpliance with chemo 
week 5  
Compliance Chemo week 5 N % 
1. Completed week 5 as per 
protocol 631 83.47 
2. Any delays, dose reduction or 
both 104 13.76 
3. No chemo during CRT 18 2.38 
4. Insufficient data 3 0.4 
 
Table A8 Patients who had RT prolongation >42 days and compliance with 
chemo week  5  
Compliance Chemo week 5 N % 
1. Completed week 5 as per 
protocol 52 55.32 
2. Any delays, dose reduction or 
both 38 40.43 


































































A: Correlation between number of patients recruited in each site and % of patients 




B: Correlation between number of patients recruited in each site and % of patients 
who received radiotherapy as per protocol in each site (sites that recruited >10 
patients) 
 
  
